Did you know there’s a tiny little device smaller than a Ritz cracker that’s one of the most powerful tools for managing type 2 diabetes? Seeing your glucose levels in real time with a CGM can improve your A1c, lower your risk for complications, and transform how you manage diabetes.

Lilly’s weekly basal insulin Onswik was just approved by the FDA, becoming the second weekly insulin therapy approved this year after Novo’s Awiqli. Find out how these new insulins work, how they compare to daily basal insulin, and who might benefit the most from making the switch.

More than 100 years after the discovery of insulin, people with type 1 diabetes finally have an FDA-approved medication to address a major complication of the condition. Discover how Kerendia works and learn how to proactively protect your kidney health.

Beta Bionics just received FDA approval for their new patch pump called Mint. Mint features a two-piece reusable and disposable design, a 200-unit insulin reservoir, three days of wear time, and doesn’t require recharging. It can be controlled from an iOS or Android smartphone and is designed to work with Dexcom G7, Dexcom G7 15 Day, and FreeStyle Libre 3 Plus CGMs. Mint is expected to launch in the U.S. in early 2027. Beta Bionics is also working on a next-gen insulin dosing algorithm called 3D Intelligence, which is under FDA review and expected to eventually power both Mint and the iLet.

Senseonics and Beta Bionics just announced a partnership to integrate the Eversense 365 implantable CGM with the iLet Bionic Pancreas. This could be the ultimate “set it and forget it” pairing in diabetes tech – a sensor that lasts an entire year and a pump that only requires basic meal announcements. The companies expect to wrap integration by the end of 2026, with a commercial launch planned after testing and regulatory requirements.